Your session is about to expire
← Back to Search
Shorter Course Hormone + Radiation Therapy for High-risk Prostate Cancer
Study Summary
This trial is testing a new, shorter course of ADT combined with standard prostate brachytherapy and hypofractionated external beam radiation therapy to see if it is effective in preventing high-risk prostate cancer from recurring or spreading.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 926 Patients • NCT01414608Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer's genetic score is 0.6 or lower.My prostate is smaller than 90 cubic centimeters.I started hormone therapy for cancer less than 60 days ago.I can take care of myself and perform daily activities.I am 18 years old or older.I do not have an active cancer that needs treatment, except for certain early-stage cancers.My scans likely show advanced T3-T4 disease, as confirmed by a radiologist.My prostate cancer is advanced, with a high Gleason score or PSA level.I have been diagnosed with prostate cancer.I have no health issues that prevent me from receiving hormone therapy, seed implantation, or pelvic radiation.My cancer has spread to lymph nodes or other parts of my body.I have had surgery on my prostate.I have a history of inflammatory bowel disease.I cannot have anesthesia or specific radiation treatments.I have had radiation therapy to my pelvic area before.Your doctor expects you to live for more than 5 years.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Group 1: Hormone Therapy and Radiation
Frequently Asked Questions
Is this experiment presently open to recruitment?
"Data on clinicaltrials.gov verifies that this research is actively enrolling patients, with the trial first being posted on October 19th 2021 and last updated November 2nd 2022."
Has the Federal Drug Administration certified Brachytherapy as an acceptable treatment?
"Brachytherapy has been given a safety rating of 2 because there is evidence to support its security, yet the efficacy remains unconfirmed."
How many physical locations are overseeing this clinical examination?
"Currently, the trial is enrolling participants at 7 different medical sites. These locations include Commack, Harrison and Montvale as well as 4 other locales. Selecting a nearby site will help minimise any travel obligations for those involved in this study."
How many volunteers are involved in this experiment?
"That is correct. Clinicaltrials.gov reveals that, as of November 2nd 2022, this clinical trial remains open and searching for 50 participants across 7 different sites - the program was initially posted on October 19th 2021."
Share this study with friends
Copy Link
Messenger